Boundless Bio nabs $105M for ecDNA-directed cancer therapy

By The Science Advisory Board staff writers

April 28, 2021 -- Boundless Bio has secured $105 million in financing to advance multiple extrachromosomal DNA (ecDNA)-directed therapeutic programs into the clinic along with an accompanying ecDNA harboring oncogene (ECHO) companion diagnostic.

EcDNA are circular units of DNA that lack centromeres but contain functional genes and are transcriptionally active. They are a main driver of gene amplification and copy number heterogeneity in cancer, particularly in solid tumors.

Boundless has built its Spyglass platform that allows it to interrogate ecDNA in cancer and find therapeutically targetable liabilities in ecDNA-derived, gene amplified tumors. Using the technology, the company has discovered three ecDNA targets and initiated drug discovery efforts for each.

The oversubscribed series B funding round was led by RA Capital Management and Nextech Invest.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter